Novel Cancer Stem Marker and Its Applicability for Grading Primary Human Gliomas.

Abstract

Poorly differentiated cell populations including tumor-initiating stem cells have been demonstrated to display a unique ability to natively internalize fragmented double-stranded DNA. Using this feature as a marker, we show that 0.1% to 6% of human glioblastoma cells from the bioptates can effectively internalize a fluorescently labeled DNA probe. Of these, using samples from 3 patients, 66% to 100% cells are also positive for CD133, a well-established surface marker of tumor-initiating glioma stem cells. Using the samples from primary malignant brain lesions (33 patients), we demonstrate that tumor grading significantly correlates ( R = .71) with the percentage of DNA-internalizing cells. No such correlation is observed for relapse samples (18 patients).

• Authors: Evgeniya V Dolgova, Sergey V Mishinov, Anastasiya S Proskurina, Ekaterina A Potter, Yaroslav R Efremov, Sergey I Bayborodin, Tamara V Tyrinova, Vyacheslav V Stupak, Alexandr A Ostatin, Elena R Chernykh, Sergey S Bogachev
• Journal: Technology in cancer research & treatment (Technol Cancer Res Treat) Vol. 17 Pg. 1533034617753812 (01 01 2018) ISSN: 1533-0338 [Electronic] United States
• PMID: 29375020 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• AC133 Antigen
• Biomarkers, Tumor
• DNA, Neoplasm

Topics

• AC133 Antigen
• Biomarkers, Tumor
• Brain Neoplasms (metabolism, pathology, surgery)
• DNA, Neoplasm (genetics, metabolism)
• Fluorescent Antibody Technique
• Glioma (genetics, metabolism, pathology, surgery)
• Humans
• Neoplasm Grading
• Neoplastic Stem Cells (metabolism, pathology)
• Tumor Cells, Cultured